Pharmacoeconomics of combination antihypertensive therapy

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Antihypertensive treatment should provide optimal health benefits while minimizing treatment costs. Most patients require a combination of drugs to achieve blood pressure goals. Two studies have shown that switching to fixed-dose combination therapy is effective, well tolerated, and cost-effective for most patients. A fixed-dose combination agent containing a diuretic and a β-blocker, an angiotensin-converting enzyme inhibitor, or an angiotensin II receptor antagonist is generally more effective, better tolerated, and does not cost more than the non-diuretic component. Therefore, the associated health-care resource costs of using these fixed-dose combination products should be less than those associated with the use of monotherapy.

Original languageEnglish (US)
Pages (from-to)S31-S36
JournalBlood Pressure Monitoring
Issue numberSUPPL. 1
StatePublished - Jan 1 2001

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine
  • Assessment and Diagnosis
  • Advanced and Specialized Nursing


Dive into the research topics of 'Pharmacoeconomics of combination antihypertensive therapy'. Together they form a unique fingerprint.

Cite this